US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.98 ▲+0.52% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.49 ▼-3.19% MSFT $529.30 ▲+0.78%
FinancialContent

Articles published by Context Therapeutics Inc.

< Previous 1 2 Next >
News headline image
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers BCAB CNTX
News headline image
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Chief Medical Officer Transition
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
News headline image
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
< Previous 1 2 Next >